Mineralys Therapeutics (MLYS) to Release Earnings on Monday

Mineralys Therapeutics (NASDAQ:MLYS) is anticipated to announce its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.12. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Trading Down 0.6%

Shares of MLYS stock opened at $40.86 on Monday. The firm has a market capitalization of $2.71 billion, a P/E ratio of -11.48 and a beta of 0.40. Mineralys Therapeutics has a 1 year low of $8.24 and a 1 year high of $44.80. The firm’s fifty day simple moving average is $36.16 and its 200 day simple moving average is $22.12.

Insiders Place Their Bets

In related news, CFO Adam Scott Levy sold 10,758 shares of the company’s stock in a transaction on Monday, October 13th. The shares were sold at an average price of $42.01, for a total value of $451,943.58. Following the completion of the transaction, the chief financial officer directly owned 116,865 shares of the company’s stock, valued at approximately $4,909,498.65. This represents a 8.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Srinivas Akkaraju purchased 588,235 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was purchased at an average price of $25.50 per share, for a total transaction of $14,999,992.50. Following the completion of the acquisition, the director owned 588,235 shares of the company’s stock, valued at approximately $14,999,992.50. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold 58,959 shares of company stock worth $2,098,393 in the last three months. 25.56% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of large investors have recently bought and sold shares of the company. Rafferty Asset Management LLC bought a new position in shares of Mineralys Therapeutics during the 2nd quarter worth approximately $776,000. Man Group plc increased its stake in Mineralys Therapeutics by 50.1% in the 2nd quarter. Man Group plc now owns 21,852 shares of the company’s stock valued at $296,000 after buying an additional 7,293 shares during the last quarter. Balyasny Asset Management L.P. lifted its position in Mineralys Therapeutics by 37.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 205,723 shares of the company’s stock worth $2,783,000 after buying an additional 56,450 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Mineralys Therapeutics by 78.9% during the 2nd quarter. Bank of America Corp DE now owns 263,356 shares of the company’s stock worth $3,563,000 after buying an additional 116,134 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at about $688,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MLYS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 22nd. Jefferies Financial Group raised their price objective on shares of Mineralys Therapeutics from $15.00 to $26.00 and gave the stock a “hold” rating in a report on Wednesday, September 3rd. Wells Fargo & Company boosted their target price on Mineralys Therapeutics from $26.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Finally, Bank of America raised their price target on Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $45.17.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.